Last reviewed · How we verify

Fecal Microbial Transplantation by capsules

Ella Therapeutics Ltd · Phase 1 active Biologic

Fecal Microbial Transplantation by capsules is a Biologic drug developed by Ella Therapeutics Ltd. It is currently in Phase 1 development. Also known as: Nivolumab.

At a glance

Generic nameFecal Microbial Transplantation by capsules
Also known asNivolumab
SponsorElla Therapeutics Ltd
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fecal Microbial Transplantation by capsules

What is Fecal Microbial Transplantation by capsules?

Fecal Microbial Transplantation by capsules is a Biologic drug developed by Ella Therapeutics Ltd.

Who makes Fecal Microbial Transplantation by capsules?

Fecal Microbial Transplantation by capsules is developed by Ella Therapeutics Ltd (see full Ella Therapeutics Ltd pipeline at /company/ella-therapeutics-ltd).

Is Fecal Microbial Transplantation by capsules also known as anything else?

Fecal Microbial Transplantation by capsules is also known as Nivolumab.

What development phase is Fecal Microbial Transplantation by capsules in?

Fecal Microbial Transplantation by capsules is in Phase 1.

Related